FNY Managed Accounts’s CytomX Therapeutics CTMX Stock Holding History

FNY Managed Accounts’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-161	Closed	-$2K	–	262
2017 Q1	$2K	Buy	+161	New	+$2.12K	0.01%	703

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

FNY Managed Accounts's CTMX Position: Q2 2017 in Review

FNY Managed Accounts sold out of CytomX Therapeutics (CTMX) in Q2 2017, closing a stake of 161 shares — an estimated $2K sold.

FNY Managed Accounts first reported a position in CTMX in Q1 2017 and held it in 1 quarter. The position peaked at $2K in Q1 2017. 90 funds tracked by Wall St. Rank hold CTMX as of Q2 2017.

FNY Managed Accounts reported no remaining CytomX Therapeutics position as of Q2 2017 after selling out during the quarter.
FNY Managed Accounts sold 161 CytomX Therapeutics shares in Q2 2017, an estimated $2K.
FNY Managed Accounts first reported a position in CytomX Therapeutics in Q1 2017 and held it in 1 quarter.
FNY Managed Accounts's CytomX Therapeutics position peaked at $2K in Q1 2017.
90 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.